Research line

Neuropharmacology and Pain


  • Adenosine and dopamine receptor-receptor interactions in the neurobiology of schizophrenia & Parkinson’s disease.
  • GPCRs & ion channels oligomerization.
  • The Parkinson’s disease-associated GPR37 receptor: a promising target for neurological diseases.
  • Targeting the sigma-1 receptor: Pain and more.
  • GPCR Optopharmacology.
  • Adenosine receptors as new targets for the treatment of atrial fibrillation.
  • Phosphorylation of NMDAR in Down syndrome and AD.
  • NMDAR mutations and intellectual disability.
  • The Gut Microbiome in Neuroinflammation and Neurodevelopmental Disorders


  • Disease / disorder characterization: Parkinson’s and Alzheimer’s disease, Pain, etc…
  • Treatment discovery: Drug design and validation
  • Assessment of new treatments: Preclinical research (i.e. animal models)
  • Methods for diagnostic: Design and development of biosensors
  • In vitro models: Cell-based disease models
  • In vivo models: Pharmacological and genetics animal models
  • Clinical data: In collaboration with Bellvitge’s Hospital
  • Development of new tools / technologies / computational methods: Fluorescence/Bioluminescence-based biosensors


Keywords: Alzheimer disease, DKK1, SAMP8, β-catenin, Wnt pathway.



Dr. Francisco Ciruela

fciruela (at)